title: Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.
abstract: OBJECTIVE
  To determine late toxicity and quality of life (QoL) in patients with localized prostate cancer after high-dose intensity-modulated radiotherapy (IMRT).
  
  
  METHODS
  This was a prospective study in patients with localized prostate adenocarcinoma who had been treated by IMRT (76 Gy) between February and November 2006. Physicians scored acute and late toxicity using the Common Terminology Criteria for Adverse Events (version 3.0). Patients completed cancer and prostate-specific QoL questionnaires (EORTC QLQ-C30 and QLQ-PR25) before IMRT (baseline) and at 2, 6, 18 and 54 months.
  
  
  RESULTS
  Data were available for 38 patients (median age, 73 years) (18% low risk; 60% intermediate risk; 32% high risk). The incidence of urinary and gastrointestinal toxicity was respectively: immediately post IMRT: 36.8% and 23.7% (grade 1), 5.3% and 5.3% (grade 2), 2.6% and 0% (grade 3); at 18 months: 23.7% and 10.3% (grade 1), 26.3% and 13.2% (grade 2), 0% and 2.6% (grade 3); at 54 months: 34.2% and 23.7% (grade 1), 5.3% and 15.8% (grade 2), 5.3% and 0% (grade 3). At 54 months, significant worsening was reported by patients for 11/19 QoL items but the worsening was clinically relevant (>10 points) for 7 items only: physical, role as well as social functioning, fatigue, pain, dyspnoea and constipation. There was no significant difference between 54-month and baseline QoL scores for global health, gastrointestinal symptoms, treatment-related symptoms and sexual function. However, there was significant - but clinically non-relevant (<10 points) - worsening of urinary symptom.
  
  
  CONCLUSIONS
  High-dose IMRT to the prostate with accurate patient positioning did not induce any clinically relevant worsening in late urinary and gastrointestinal QoL at 54 months. Impaired physical and role functioning may be related to age and comorbidities.
authors.affiliation: Integrated Center of Oncology René Gauducheau, Nantes-St Herblain, France.
authors.forename: Aurore
authors.initials: A
authors.lastname: Goineau
authors.forename: Virginie
authors.initials: V
authors.lastname: Marchand
authors.forename: Jérome
authors.initials: J
authors.lastname: Rigaud
authors.forename: Sylvain
authors.initials: S
authors.lastname: Bourdin
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Rio
authors.forename: Loic
authors.initials: L
authors.lastname: Campion
authors.forename: Angélique
authors.initials: A
authors.lastname: Bonnaud-Antignac
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Mahé
authors.forename: Stéphane
authors.initials: S
authors.lastname: Supiot
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology / Q000473:pathology / Q000523:psychology / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D019583:Dose Fractionation, Radiation; D005500:Follow-Up Studies; D005767:Gastrointestinal Diseases / Q000453:epidemiology / Q000209:etiology; D041981:Gastrointestinal Tract / Q000473:pathology / Q000528:radiation effects; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000523:psychology / Q000532:radiotherapy*; D011788:Quality of Life; D011832:Radiation Injuries / Q000453:epidemiology / Q000209:etiology; D011879:Radiotherapy Dosage; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods; D011795:Surveys and Questionnaires; D001743:Urinary Bladder / Q000473:pathology / Q000528:radiation effects; D001745:Urinary Bladder Diseases / Q000453:epidemiology / Q000209:etiology